23andMe Holding Co.

Equities

ME

US90138Q1085

Healthcare Facilities & Services

Market Closed - Nasdaq 04:00:00 2024-07-19 pm EDT 5-day change 1st Jan Change
0.442 USD -6.79% Intraday chart for 23andMe Holding Co. -8.47% -51.61%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
23andMe to Offer Free Blood Testing for Members in Pilot Program MT
23andMe Holding Co. and Nightingale Health Plc Announce Strategic Collaboration to Pilot Blood Biomarker Panel CI
Sector Update: Health Care Stocks Advance Late Afternoon MT
Sector Update: Health Care Stocks Retreat Monday Afternoon MT
23andMe Under Scrutiny by UK, Canadian Privacy Regulators Over October Data Breach MT
23andMe Under Scrutiny by UK, Canadian Privacy Regulators Over October 2023 Data Breach MT
Canada, UK launched joint probe into 23andMe data breach, says Canada RE
23andMe Faces Joint Probe From UK Information Commissioner's Office, Canada's Privacy Commissioner Office Over 2023 Data Breach MT
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, Targeting CD200R1, at the 2024 ASCO Annual Meeting CI
Earnings Flash (ME) 23ANDME Reports Q4 Revenue $64M, vs. Street Est of $61.5M MT
23andMe Q4 Loss Widens, Revenue Decreases MT
Transcript : 23andMe Holding Co., Q4 2024 Earnings Call, May 23, 2024
23andMe Holding Co. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
23andMe Holding Co. Reports Unaudited Consolidated Goodwill Impairment for the Fourth Quarter Ended March 31, 2024 CI
Alibaba Cuts ADS Holdings by 60% in Q1 MT
Sector Update: Health Care Stocks Rise in Late Afternoon Trading MT
Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading MT
23andMe Unit Offers Petros Pharmaceuticals' Impotency Medication MT
23andMe Holding Co. to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology Annual Meeting CI
Petros, Lemonaid Health Collaborate to Expand Stendra Availability MT
Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup DJ
US Equity Markets Close Mixed Thursday MT
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading MT
Sector Update: Health Care Stocks Ease in Afternoon Trading MT
Sector Update: Health Care MT
Chart 23andMe Holding Co.
More charts
23andMe Holding Co. is a genetics-led consumer healthcare and biopharmaceutical company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.442 USD
Average target price
1.315 USD
Spread / Average Target
+197.51%
Consensus
  1. Stock Market
  2. Equities
  3. ME Stock
  4. News 23andMe Holding Co.
  5. Sector Update: Health Care Stocks Rise in Late Afternoon Trading